Cargando…

Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen

Background: Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with type 2 diabetes, inadequately controlled on basal insulin, initiating and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergenstal, Richard M., Peyrot, Mark, Dreon, Darlene M., Aroda, Vanita R., Bailey, Timothy S., Brazg, Ronald L., Frias, Juan P., Johnson, Mary L., Klonoff, David C., Kruger, Davida F., Ramtoola, Shenaz, Rosenstock, Julio, Serusclat, Pierre, Weinstock, Ruth S., Naik, Ramachandra G., Shearer, David M., Zraick, Vivien, Levy, Brian L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532545/ https://www.ncbi.nlm.nih.gov/pubmed/31025878 http://dx.doi.org/10.1089/dia.2018.0298

Ejemplares similares

Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch
por: Peyrot, Mark, et al.
Publicado: (2018)

Extended insulin boluses cannot control postprandial glycemia as well as a standard bolus in children and adults using insulin pump therapy
por: Lopez, Prudence, et al.
Publicado: (2014)

Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen
por: Adolfsson, Peter, et al.
Publicado: (2020)

Efficacy of bolus insulin calculation by a mobile-based bolus advisor: An open label clinical trial
por: Siavash, Mansour, et al.
Publicado: (2015)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Missed Insulin Boluses for Snacks in Youth With Type 1 Diabetes
por: VanderWel, Brandon W., et al.
Publicado: (2010)

A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
por: Johnson, Mary L., et al.
Publicado: (2022)

Effect of Bolus Insulin Administration Followed by a Continuous Insulin Infusion on Diabetic Ketoacidosis Management
por: Brown, Hannah D., et al.
Publicado: (2018)

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
por: Goldenberg, Ronald M., et al.
Publicado: (2021)

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016)

Optimal prandial timing of bolus insulin in diabetes management: a review
por: Slattery, D., et al.
Publicado: (2017)

Accuracy of Bolus and Basal Rate Delivery of Different Insulin Pump Systems
por: Freckmann, Guido, et al.
Publicado: (2019)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Impact of Pocket Insulin Dosing Guide on Utilization of Basal/Bolus Insulin by Internal Medicine Resident Physicians
por: Mamillapalli, Chaitanya K, et al.
Publicado: (2018)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Five Simple Steps to Optimize Bolus Insulin Therapy in Type 2 Diabetes
por: Peters, Kyle R., et al.
Publicado: (2017)

An Insulin Bolus Advisor for Type 1 Diabetes Using Deep Reinforcement Learning
por: Zhu, Taiyu, et al.
Publicado: (2020)

Making Sense of BGM and CGM Data for a Basal-Bolus Insulin User
Publicado: (2020)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

Impact of erroneous meal insulin bolus with dual-hormone artificial pancreas using a simplified bolus strategy - A randomized controlled trial
por: Gingras, Véronique, et al.
Publicado: (2018)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe, Shinya, et al.
Publicado: (2011)

Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]
por: Cavan, David A, et al.
Publicado: (2012)

Regular insulin, rather than rapid‐acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
por: Kuroda, Akio, et al.
Publicado: (2013)

Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes
por: Bellido, Virginia, et al.
Publicado: (2015)

Basal-bolus or premixed? Shedding light on optimal insulin regime for type 1 diabetes
por: Louise Walton, Emma
Publicado: (2018)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
por: Heller, Simon, et al.
Publicado: (2013)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
por: Goldenberg, Ronald M., et al.
Publicado: (2023)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Correlates of Insulin Injection Omission
por: Peyrot, Mark, et al.
Publicado: (2010)

The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy
por: Ozturkmen, Yuksel Asli, et al.
Publicado: (2020)

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)

Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy
por: Abrahamson, Martin J., et al.
Publicado: (2012)

Mealtime insulin BOLUS score increases prior to clinic visits in youth with type 1 diabetes
por: McConville, Andrew, et al.
Publicado: (2020)

A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control
por: Chen, Bo Zhi, et al.
Publicado: (2020)

Predicting the Need for Basal-Bolus Insulin in Hospitalized Patients With Hyperglycemia: Is Sliding Scale Sometimes the Answer?
por: Jankovic, Ivana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_umld4hlak40phfrcjn0to8un0n